Physician profile
Scott A Markham
NPI 1700994308
$5,183.24
in general payments reported to CMS, 2019-2025
43 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $338 · 2021: $929 · 2022: $679 · 2023: $536 · 2024: $666 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.45 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $702.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $561.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $435.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $430.44 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $405.76 | 2019-2024 | Prolia, Evenity, Repatha |
| Pfizer INC. | $346.17 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $300.27 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.65 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $178.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $146.94 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.87 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $124.82 | 2019-2025 | Trintellix |
| Musculoskeletal Transplant Foundation INC. | $117.38 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $89.09 | 2021 | |
| Amarin Pharma, INC. | $67.52 | 2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $60.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.74 | 2019-2021 | |
| Vbi Vaccine (Delaware) INC. | $56.16 | 2022-2023 | Prehevbrio |
| Abbvie INC. | $55.91 | 2021-2022 | |
| Genentech USA, INC. | $47.79 | 2019-2020 | |
| Abbott Laboratories | $45.66 | 2024-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $45.43 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $45.20 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $41.84 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Mylan Specialty L.P. | $40.71 | 2024 | Yupelri |
| Eisai INC. | $38.87 | 2021 | |
| Bioxcel Therapeutics, INC. | $36.51 | 2023 | Igalmi |
| Astellas Pharma US INC | $33.62 | 2019 | |
| Exact Sciences Corporation | $29.02 | 2023-2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $27.65 | 2021-2023 | |
| Biogen, INC. | $27.03 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $26.26 | 2023 | Quviviq |
| Organogenesis INC. | $23.67 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.24 | 2022 | |
| Lundbeck LLC | $22.29 | 2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $22.10 | 2025 | Koselugo |
| Medtronic, INC. | $20.51 | 2023 | Minimed 770g |
| Dexcom, INC. | $18.54 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.43 | 2025 | Gvoke Hypopen |
| Agile Therapeutics, INC. | $15.19 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.44 | 2020 | |
| Depuy Synthes Sales INC. | $12.17 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Markham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.